Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.64 USD | +3.05% | -7.80% | -39.55% |
May. 13 | Ajax Therapeutics, Inc. announced that it has received $95 million in funding from a group of investors | CI |
May. 07 | Ansys Partners With Schrodinger to Accelerate Materials Development | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.55% | 1.57B | B | ||
+17.29% | 3,278B | C+ | ||
+14.76% | 90.53B | B | ||
+14.44% | 85.46B | B+ | ||
+38.44% | 52.93B | D+ | ||
-16.74% | 52.56B | B+ | ||
+35.44% | 47.67B | D+ | ||
-31.54% | 42.38B | B- | ||
+82.42% | 42.43B | D+ | ||
-0.80% | 27.82B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SDGR Stock
- Ratings Schrödinger, Inc.